製品: Keap1 Antibody
カタログ: AF5266
タンパク質の説明: Rabbit polyclonal antibody to Keap1
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat, Monkey
予測: Pig, Bovine, Horse, Sheep, Rabbit, Dog
分子量: 70 kDa; 70kD(Calculated).
ユニプロット: Q14145
RRID: AB_2837752

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat,Monkey
予測:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%)
クローナリティ:
Polyclonal
特異性:
Keap1 Antibody detects endogenous levels of total Keap1.
RRID:
AB_2837752
引用形式: Affinity Biosciences Cat# AF5266, RRID:AB_2837752.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

Cytosolic inhibitor of Nrf2; INrf 2; INrf2; Keap 1; KEAP1; KEAP1_HUMAN; Kelch like ECH associated protein 1; Kelch like family member 19; Kelch like protein 19; Kelch-like ECH-associated protein 1; Kelch-like protein 19; KIAA0132; KLHL 19; KLHL19; MGC10630; MGC1114; MGC20887; MGC4407; MGC9454;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
発現特異性:
Q14145 KEAP1_HUMAN:

Broadly expressed, with highest levels in skeletal muscle.

タンパク質の説明:
Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression.
タンパク質配列:
MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTC

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Chicken
60
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q14145 基板として

Site PTM Type Enzyme
Ubiquitination
Y33 Phosphorylation
K39 Ubiquitination
T43 Phosphorylation
Y54 Phosphorylation
T55 Phosphorylation
T60 Phosphorylation
K61 Ubiquitination
K84 Ubiquitination
Y85 Phosphorylation
K97 Ubiquitination
K108 Ubiquitination
T112 Phosphorylation
K131 Acetylation
Y141 Phosphorylation
C273 S-Nitrosylation
T277 Phosphorylation
K287 Ubiquitination
C288 S-Nitrosylation
S293 Phosphorylation
S295 Phosphorylation
K298 Ubiquitination
K312 Ubiquitination
S599 Phosphorylation Q02156 (PRKCE)
S602 Phosphorylation Q02156 (PRKCE)
K615 Ubiquitination

研究背景

機能:

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination. KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes. In response to oxidative stress, different electrophile metabolites trigger non-enzymatic covalent modifications of highly reactive cysteine residues in KEAP1, leading to inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying enzymes. In response to selective autophagy, KEAP1 is sequestered in inclusion bodies following its interaction with SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and activation of NFE2L2/NRF2. The BCR(KEAP1) complex also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 sequestering activity and degradation. The BCR(KEAP1) complex also targets BPTF and PGAM5 for ubiquitination and degradation by the proteasome.

PTMs:

Non-enzymatic covalent modifications of reactive cysteines by electrophile metabolites inactivate the BCR(KEAP1) complex. Accumulation of fumarate promotes the formation of cysteine S-succination (S-(2-succinyl)cysteine), leading to inactivate the BCR(KEAP1) complex and promote NFE2L2/NRF2 nuclear accumulation and activation (By similarity). Nitric oxide-dependent 8-Nitro-cGMP formation promotes cysteine guanylation (S-cGMP-cysteine), leading to NFE2L2/NRF2 nuclear accumulation and activation (By similarity). Itaconate, an anti-inflammatory metabolite generated in response to lipopolysaccharide, alkylates cysteines, activating NFE2L2/NRF2. Methylglyoxal, a reactive metabolite that accumulates when the glycolytic enzyme PGK1 is inhibited, promotes formation of a methylimidazole cross-link between proximal Cys-151 and Arg-135 on another KEAP1 molecule, resulting in an inactive dimer that inactivates the BCR(KEAP1) complex.

Degraded via a proteasomal-independent process during selective autophagy: interaction with phosphorylated SQSTM1/p62 sequesters KEAP1 in inclusion bodies, leading to its degradation.

Auto-ubiquitinated by the BCR(KEAP1) complex. Quinone-induced oxidative stress, but not sulforaphane, increases its ubiquitination. Ubiquitination and subsequent degradation is most pronounced following prolonged exposure of cells to oxidative stress, particularly in glutathione-deficient cells that are highly susceptible to oxidative stress.

細胞の位置付け:

Cytoplasm. Nucleus.
Note: Mainly cytoplasmic (PubMed:15601839). In response to selective autophagy, relocalizes to inclusion bodies following interaction with SQSTM1/p62 (PubMed:20452972).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Broadly expressed, with highest levels in skeletal muscle.

サブユニット構造:

Component of the BCR(KEAP1) E3 ubiquitin ligase complex, at least composed of 2 molecules of CUL3, 2 molecules of KEAP1, and RBX1. Interacts with NFE2L2/NRF2; the interaction is direct. Forms a ternary complex with NFE2L2/NRF2 and PGAM5. Interacts with (phosphorylated) SQSTM1/p62; the interaction is direct and inactivates the BCR(KEAP1) complex by sequestering it in inclusion bodies, promoting its degradation. Interacts with NFE2L1. Interacts with BPTF and PTMA. Interacts with MAP1LC3B. Interacts indirectly with ENC1. Interacts with SESN1 and SESN2. Interacts with HSP90AA1 and HSP90AB1.

(Microbial infection) Interacts with ebolavirus protein VP24; this interaction activates transcription factor NFE2L2/NRF2 by blocking its interaction with KEAP1.

タンパク質ファミリー:

KEAP1 contains reactive cysteine residues that act as sensors for endogenously produced and exogenously encountered small molecules, which react with sulfhydryl groups and modify the cysteine sensors, leading to impair ability of the BCR(KEAP1) complex to ubiquitinate target proteins.

The Kelch repeats mediate interaction with NFE2L2/NRF2, BPTF and PGAM5.

Belongs to the KEAP1 family.

研究領域

· Genetic Information Processing > Folding, sorting and degradation > Ubiquitin mediated proteolysis.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

参考文献

1). Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death & Disease, 2021 (PubMed: 34775496) [IF=9.0]

Application: WB    Species: Human    Sample: HCT116 and DLD-1 cells

Fig. 3 Combination treatment with RSL3 and cetuximab inhibits Nrf2/HO-1 axis in KRAS mutant CRC cells. A The protein levels of Keap1, Nrf2 and HO-1 in HCT116 and DLD-1 cells were measured by western blotting after treatment with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. B Knockdown of Nrf2 by siRNA reduced the expression of Nrf2 and the protein levels of Nrf2 and HO-1 after treatment with RSL3 (1 μM) for 24 h. C siRNA-mediated knockdown of Nrf2 increased the sensitivity of HCT116 and DLD-1 cells to RSL3. D–F The levels of MDA, lipid ROS and intracellular iron were measured in Nrf2-silenced HCT116 and DLD-1 cells pretreated with or without RSL3 (1 μM). Scale bar, 100 μm. **P < 0.01; *P < 0.05.

2). Total flavonoids of Inula japonica alleviated the inflammatory response and oxidative stress in LPS-induced acute lung injury via inhibiting the sEH activity: Insights from lipid metabolomics. PHYTOMEDICINE, 2022 (PubMed: 36150346) [IF=7.9]

3). Ginsenoside Rg1 prevents bone marrow mesenchymal stem cell senescence via NRF2 and PI3K/Akt signaling. Free radical biology & medicine, 2021 (PubMed: 34364981) [IF=7.4]

Application: WB    Species: Mice    Sample: liver tissues

Fig. 7 Ginsenoside Rg1 activates NRF2 by promoting the degradation of KEAP1. a–b Western blot analysis of KEAP1 levels from Rg1-treated MSCs induced by D-gal. c Representative immunofluorescence pictures of KEAP1 mouse thighbone from each group (normal, Rg1, D-gal, Rg1+D-gal). d–h MSCs pre-treated with solvent or MG132 (10 μM), CQ (20 μM) or 3-MA (5 mM) for 4 h and then treated with Rg1 for 24 h (kept with MG132, CQ or 3MA), and NRF2, KEAP1 and LC3 expression levels in total protein were detected by western blot. i Atg7, P62, LC3 expression levels in total protein from each group (normal, Rg1, D-gal, D-gal+Rg1). j Rg1 enhanced the interaction between P62 and KEAP1. Representative blots of PLA. The pictures show a maximum intensity projection of the raw image based on 20 z-planes. PLA signals are shown in red and the nuclei in blue. The nucleus image was acquired in one z-plane. k-m MSCs were treated with Rg1, D-gal, and XRK3F2 (a P62 inhibitor, 5 μM), and then NRF2, KEAP1, LC3 (k), p21, p16 (m) expression levels in total protein from each group were detected by western blot, as well as the interaction between NRF2 and KEAP1 were assayed with co-IP (l). Bars represent 100 μm (c), 20 μm (j). Data in b, e, g represent mean ± SD (n=3, *P < 0.05; ns indicates no significance; one-way ANOVA)

4). Echinacoside alleviates hypobaric hypoxia-induced memory impairment in C57 mice. PHYTOTHERAPY RESEARCH, 2019 (PubMed: 30768741) [IF=7.2]

5). Ellagic acid ameliorates arsenic-induced neuronal ferroptosis and cognitive impairment via Nrf2/GPX4 signaling pathway. Ecotoxicology and environmental safety, 2024 (PubMed: 39128446) [IF=6.8]

Application: WB    Species: Rat    Sample: hippocampus and HT22 cells

Fig. 6. The impact of ellagic acid treatment on arsenic-induced Nrf2/Keap1 signaling pathway in the hippocampus and HT22 cells. (A) Western blot for p-Nrf2, Nrf2 and Keap1 in the hippocampus. (B-D) Relative density analysis of the p-Nrf2, Nrf2 and Keap1 protein bands in the hippocampus. (E) Quantification of Keap1 mRNA levels in the hippocampus. (F) Western blot for Nucleus Nrf2, Nrf2 and Keap1 in HT22 cells. (G-I) Relative density analysis of the Nucleus Nrf2, Nrf2 and Keap1 protein bands in HT22 cells. (J) Quantification of Keap1 mRNA levels in HT22 cells. Data are presented as mean ± SD (n=3). * significant difference compared to the control group (*P

6). Dose-and time-effects responses of Nonylphenol on oxidative stress in rat through the Keap1-Nrf2 signaling pathway. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2021 (PubMed: 33836420) [IF=6.8]

Application: WB    Species: Rat    Sample: liver tissue

Fig. 3. The Keap1 (A), cytoplasmic Nrf2 (B) and nuclear Nrf2 (C) protein expression in rat liver of control and NP treatment (low, middle and high dose) groups for 7, 14 and 28 days. Protein levels were normalized against those of GAPDH and PCNA. Representative immunoblots are also shown below the graphs. Data are presented as mean ± S.D.(n = 3). * p<0.05 and * * p < 0.01 versus C group. & p < 0.05 versus NPL group.

7). Sonneratia apetala seed oil attenuates potassium oxonate/hypoxanthine-induced hyperuricemia and renal injury in mice. Food & Function, 2021 (PubMed: 34606558) [IF=6.1]

8). Industrially Produced Rice Protein Ameliorates Dextran Sulfate Sodium-Induced Colitis via Protecting the Intestinal Barrier, Mitigating Oxidative Stress, and Regulating Gut Microbiota. Journal of Agricultural and Food Chemistry, 2022 (PubMed: 35412826) [IF=6.1]

9). Therapeutic role of D-pinitol on experimental colitis via activating Nrf2/ARE and PPAR-γ/NF-κB signaling pathways. Food & Function, 2021 (PubMed: 33625409) [IF=6.1]

10). Drug D, a Diosgenin Derive, Inhibits L-Arginine-Induced Acute Pancreatitis through Meditating GSDMD in the Endoplasmic Reticulum via the TXNIP/HIF-1α Pathway. Nutrients, 2022 (PubMed: 35807771) [IF=5.9]

もっと読みます

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.